{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:10:12Z","timestamp":1788988212687,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.annder.2026.103502","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:45:36Z","timestamp":1778751936000},"page":"103502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anifrolumab for refractory cutaneous manifestations of amyopathic dermatomyositis"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3052-8013","authenticated-orcid":false,"given":"V.","family":"Horiot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8045-0180","authenticated-orcid":false,"given":"M.-E.","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-6360","authenticated-orcid":false,"given":"M.-S.","family":"Doutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2026.103502_b0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11926-014-0465-0","article-title":"Amyopathic dermatomyositis: definitions, diagnosis, and management","volume":"16","author":"Bailey","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.annder.2026.103502_b0010","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.annder.2026.103502_b0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.annder.2026.103502_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.42983","article-title":"Understanding the role of type I interferons in cutaneous lupus and dermatomyositis: toward better therapeutics","volume":"77","author":"Hile","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.annder.2026.103502_b0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2026.103502_b0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","article-title":"Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment","volume":"160","author":"Shaw","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2026.103502_b0035","article-title":"A novel treatment for skin manifestations in dermatomyositis: a case report","volume":"16","author":"Srinivasa Murthy","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.annder.2026.103502_b0040","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2024.07.1491","article-title":"Anifrolumab in recalcitrant cutaneous dermatomyositis: a multicenter retrospective cohort study","volume":"91","author":"Shaw","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2026.103502_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11792","article-title":"Recalcitrant dermatomyositis treated with anifrolumab","volume":"7","author":"Chaudhary","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.annder.2026.103502_b0050","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/bjd\/ljaf064","article-title":"Improvement in dermatomyositis-associated muscle disease with anifrolumab","volume":"192","author":"Shayegan","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2026.103502_b0055","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/ijd.17675","article-title":"Successful treatment of refractory cutaneous dermatomyositis with anifrolumab","volume":"64","author":"Helm","year":"2025","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2026.103502_b0060","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ced\/llae476","article-title":"Anifrolumab use in refractory dermatomyositis: a case report and literature review","volume":"50","author":"Claudio-Oliva","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2026.103502_b0065","article-title":"Anifrolumab in refractory dermatomyositis and antisynthetase syndrome","volume":"2025","author":"Soares","year":"2025","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.annder.2026.103502_b0070","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ard.2025.02.002","article-title":"Rapid clinical and transcriptomic response to anifrolumab in refractory anti-TIF1\u03b3\u2013positive juvenile dermatomyositis","volume":"84","author":"Triaille","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2026.103502_b0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03009742.2025.2503573","article-title":"Anifrolumab for refractory dermatomyositis: a case series","volume":"54","author":"Rahbek","year":"2025","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.annder.2026.103502_b0080","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1093\/rheumatology\/keaf388","article-title":"Improvement of recalcitrant multisystem disease in dermatomyositis with anifrolumab: a case series","volume":"64","author":"Patel","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.annder.2026.103502_b0085","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/pde.16012","article-title":"Anifrolumab in refractory juvenile dermatomyositis","volume":"43","author":"Barrutia-Etxebarria","year":"2026","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.annder.2026.103502_b0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:32:19Z","timestamp":1788985939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963826000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0151963826000360"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2026.103502","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anifrolumab for refractory cutaneous manifestations of amyopathic dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2026.103502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103502"}}